文献リスト

1）Wagner HN, Burns DH, Dannals RF, et al. Imaging dopamine receptors in the human brain by positron tomography. Science. 1983; 221: 1264-6

2）佐々木貴浩．EBMに基づく核医学の選択　脳核医学神経伝達機能測定．INNERVISION. 2004; 19: 66-71

3）佐々木貴浩，天野隆弘，橋本　順，他．ドパミントランスポータ及び受容体イメージ剤を用いた錐体外路系疾患の診断．脳と神経．2003; 55: 57-64

4）鳥塚莞爾，水野美邦，久保敦司，他．ドパミンD2受容体イメージング剤123I-IBFの第2相臨床試験. 核医学．1999; 36: 845-64

5）イオフルパン診療ガイドライン

6）Lavalaye J, Booij J, Reneman L, et al. Effect of age and gender on dopamine transporter imaging with [123I]FP-CIT SPET in healthy volunteers. Eur J Nucl Med. 2000; 27: 867-9

7）Booij J, de Jong J, de Bruin K, et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. J Nucl Med. 2007; 48. 359-66

8）Grosset DG, Tatsch K, Oertel WH, et al. Safety Analysis of 10 Clinical Trials and for 13 Years After First Approval of Ioflupane 123I Injection (DaTscan). J Nucl Med. 2014; 55: 1281-7

9）Tossici-Bolt L, Hoffmann SM, Kemp PM, et al. Quantification of [123I]FP-CIT SPECT brain images: an accurate technique for measurement of the specific binding ratio. Eur J Nucl Med Mol Imaging. 2006; 33: 1491-9

10）Koch W, Unterrainer M, Xiong G, et al. Extrastriatal binding of [123I]FP-CIT in the thalamus and pons: gender and age dependencies assessed in a European multicentre database of healthy controls. Eur J Nucl Med Mol Imaging. 2014; 41: 1938-46

11）Lee CS, Kim SJ, Oh SJ, et al. Uneven age effects of [18F]FP-CIT binding in the striatum of Parkinsonʼs disease. Ann Nucl Med. 2014; 28: 874-9

12）Bernheimer H, Birkmayer W, Hornykiewicz O, et al. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci. 1973; 20: 415-55

13）Fearnley JM, Lees AJ. Ageing and Parkinsonʼs disease: substantia nigra regional selectivity. Brain. 1991; 114 (Pt 5): 2283-301

14）Sawle GV, Playford ED, Burn DJ, et al. Separating Parkinsonʼs disease from normality. Discriminant function analysis of fluorodopa F 18 positron emission tomography data. Arch Neurol. 1994; 51: 237-43

15）Piccini P, Morrish PK, Turjanski N, et al. Dopaminergic function in familial Parkinsonʼs disease: a clinical and 18F-dopa positron emission tomography study. Ann Neurol. 1997; 41: 222-9

16）Booij J, Knol RJ. SPECT imaging of the dopaminergic system in (premotor) Parkinsonʼs disease. Parkinsonism Relat Disord. 2007; 13 Suppl 3: S425-8

17）Iranzo A, Valldeoriola F, Lomeña F, et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. Lancet Neurol. 2011; 10: 797-805

18）Stern MB, Lang A, Poewe W. Toward a redefinition of Parkinsonʼs disease. Mov Disord. 2012; 27: 54-60

19）Benamer HT, Patterson J, Wyper DJ, et al. Correlation of Parkinsonʼs disease severity and duration with 123I-FP-CIT SPECT striatal uptake. Mov Disord. 2000; 15: 692-8

20）Tolosa E, Borght TV, Moreno E. Accuracy of DaTSCAN (123I-Ioflupane) SPECT in diagnosis of patients with clinically uncertain parkinsonism: 2-year follow-up of an open-label study. Mov Disord. 2007; 22: 2346-51

21）Ravina B, Marek K, Eberly S, et al. Dopamine transporter imaging is associated with long-term outcomes in Parkinsonʼs disease. Mov Disord. 2012; 27: 1392-7

22）Whone AL, Watts RL, Stoessl AJ, et al; REAL-PET Study Group. Slower progression of Parkinsonʼs disease with ropinirole versus levodopa: The REAL-PET study. Ann Neurol. 2003; 54: 93-101

23）Sawle GV, Myers R. The role of positron emission tomography in the assessment of human neuro-transplantation. Trends Neurosci. 1993; 16: 172-6

24）McKeith IG, Dickson DW, Lowe J, et al; Consortium on DLB. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. Neurology. 2005; 65: 1863-72

25）McKeith I, OʼBrien J, Walker Z, et al; DLB Study Group. Sensitivity and specificity of dopamine transporter imaging with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet Neurol. 2007; 6: 305-13

26）Walker Z, Jaros E, Walker RW, et al. Dementia with Lewy bodies: a comparison of clinical diagnosis, FP-CIT single photon emission computed tomography imaging and autopsy. J Neurol Neurosurg Psychiatry. 2007; 78: 1176-81

27）Roselli F, Pisciotta NM, Perneczky R, et al. Severity of neuropsychiatric symptoms and dopamine transporter levels in dementia with Lewy bodies: a 123I-FP-CIT SPECT study. Mov Disord. 2009; 24: 2097-103

28）Ziebell M, Andersen BB, Pinborg LH, et al. Striatal dopamine transporter binding does not correlate with clinical severity in dementia with Lewy bodies. J Nucl Med. 2013; 54: 1072-6

29）Siepel FJ, Rongve A, Buter TC, et al. (123I)FP-CIT SPECT in suspected dementia with Lewy bodies: a longitudinal case study. BMJ Open. 2013; 3

30）OʼBrien JT, Colloby S, Fenwick J, et al. Dopamine transporter loss visualized with FP-CIT SPECT in the differential diagnosis of dementia with Lewy bodies. Arch Neurol. 2004; 61: 919-25

31）Marek K, Jennings D, Seibyl J. Imaging the dopamine system to assess disease-modifying drugs: studies comparing dopamine agonists and levodopa. Neurology. 2003; 61(6 Suppl 3): S43-8

32）Fahn S. Does levodopa slow or hasten the rate of progression of Parkinsonʼs disease? J Neurol. 2005; 252 Suppl 4: IV37-42

33）Schneider SA, Edwards MJ, Mir P, et al. Patients with adult-onset dystonic tremor resembling parkinsonian tremor have scans without evidence of dopaminergic deficit (SWEDDs). Mov Disord. 2007; 22: 2210-5

34）Batla A, Erro R, Stamelou M, et al. Patients with scans without evidence of dopaminergic deficit: A long-term follow-up study. Mov Disord. 2014 Oct 28. [Epub ahead of print]

35）Benamer TS, Patterson J, Grosset DG, et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord. 2000; 15: 503-10

36）Gerschlager W, Bencsits G, Pirker W, et al. [123I]beta-CIT SPECT distinguishes vascular parkinsonism from Parkinsonʼs disease. Mov Disord. 2002; 17: 518-23

37）Ouchi Y, Nakayama T, Kanno T, et al. In vivo presynaptic and postsynaptic striatal dopamine functions in idiopathic normal pressure hydrocephalus. J Cereb Blood Flow Metab. 2007; 27: 803-10

38）Gaig C, Marti MJ, Tolosa E, et al. 123I-ioflupane SPECT in the diagnosis of suspected psychogenic Parkinsonism. Mov Disord. 2006; 21: 1994-8

39）Tinazzi M, Antonini A, Bovi T, et al. Clinical and [123I]FP-CIT SPET imaging follow-up in patients with drug-induced parkinsonism. J Neurol. 2009; 256: 910-5

40）Jeon BS, Jeong JM, Park SS, et al. Dopamine transporter density measured by [123I]beta-CIT single-photon emission computed tomography is normal in doparesponsive dystonia. Ann Neurol. 1998; 43: 792-800

41）Naumann M, Pirker W, Reiners K, et al. [123I]beta-CIT single-photon emission tomography in DOPA-responsive dystonia. Mov Disord. 1997; 12: 448-51

42）Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010; 81: 5-12

43）Catafau AM, Tolosa E; DaTSCAN Clinically Uncertain Parkinsonian Syndromes Study Group. Impact of dopamine transporter SPECT using 123I-Ioflupane on diagnosis and management of patients with clinically uncertain Parkinsonian syndromes. Mov Disord. 2004; 19: 1175-82

44）Scherfler C, Schwarz J, Antonini A, et al. Role of DAT-SPECT in the diagnostic work up of parkinsonism. Mov Disord. 2007; 22: 1229-38

45）Roselli F, Pisciotta NM, Pennelli M, et al. Midbrain SERT in degenerative parkinsonisms: a 123I-FP-CIT SPECT study. Mov Disord. 2010; 25: 1853-9

46）Ishibashi K, Saito Y, Murayama S, et al. Validation of cardiac (123)I-MIBG scintigraphy in patients with Parkinsonʼs disease who were diagnosed with dopamine PET. Eur J Nucl Med Mol Imaging. 2010; 37: 3-11

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp